Spermosens AB

Developer of revolutionizing medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments. Spermosens is listed on Spotlight Stock Market, Stockholm, Sweden.

With Spermosens first product, JUNO- Checked, it will – for the first time – be possible to determine a sperms ability to fertilize the egg cell. This in turn enables the IVF clinic to choose the appropriate fertilization treatment. Today, around 85 percent of IVF treatments fail. Being able to determine the sperm’s ability to fertilize the egg cell is expected to cause to a reduction in the number of IVF-treatments. This leads to:

  • Reduced waiting period for childless couples
  • Less negative phycological effects
  • Reduced cost for the couples in treatment
  • Reduced need for hormonal treatments of the female
  • Increased capacity of each IVF clinic
  • Improved financial outlook for IVF clinics